Transforming growth factor-beta in benign and malignant prostate.

¹Department of Urology, Northwestern University Medical School, Chicago, Illinois 60611, USA. c-lee7@nwu.edu

|May 27, 1999

Summary

Transforming growth factor-beta (TGF-beta) plays a dual role in prostate cancer. While inhibiting benign growth, it promotes malignant progression by suppressing immune function and enhancing tumor growth.

Area of Science:

Oncology
Cell Biology
Immunology

Background:

Reviews the cellular functions of transforming growth factor-beta (TGF-beta) in both benign and malignant prostate conditions.
Highlights TGF-beta's role in regulating cell growth, differentiation, and apoptosis in the prostate.

Purpose of the Study:

To elucidate the distinct mechanisms of TGF-beta action in benign prostatic hyperplasia versus prostate cancer.
To investigate the impact of TGF-beta receptor expression and production on prostate cancer progression.

Main Methods:

Analysis of TGF-beta's paracrine and autocrine signaling pathways in prostate epithelial and stromal cells.
Examination of changes in TGF-beta receptor expression and TGF-beta production during malignant transformation.
Utilized a rat prostate cancer model to assess the role of TGF-beta in tumor immunity and progression.

Main Results:

In benign conditions, TGF-beta inhibits proliferation and induces apoptosis in epithelia, and promotes smooth muscle differentiation in stroma.
Malignant transformation involves loss of functional TGF-beta receptors and overproduction of TGF-beta.
Overproduced TGF-beta promotes extracellular matrix production, angiogenesis, and immune suppression, enhancing prostate cancer tumorigenicity.

Conclusions:

TGF-beta's immunosuppressive effect is a primary driver of prostate cancer progression.
Future therapeutic strategies should target TGF-beta signaling pathways for prostate cancer eradication.

Related Experiment Videos

Transforming growth factor-beta in benign and malignant prostate.

Related Concept Videos

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02 TeV with the ATLAS Detector.

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36 TeV with the ATLAS Detector at the LHC.

Years of Life Lost in Incidental Prostate Cancer.

Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer.

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia.

Temporal Trends of Metastatic Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era in the United States.

Holmium Laser Enucleation of the Prostate (HoLEP) With Proactive Preservation of One Lateral Lobe: A Technique for Benign Prostatic Hyperplasia to Preserve Sexual Function.

Clinical Variable-Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation.

Cuproptosis-related Gene SLC31A1 Correlates with M2 Macrophage Infiltration and Serves as a Potential Therapeutic Target in Glioma: A Comprehensive Analysis of 1573 Samples from TCGA and CGGA Databases.

Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trials.

Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.

Longitudinal drug response assessment of tumor organoids based on optical attenuation coefficient and multi-dimensional morphological characterization.

Nanosensitive optical coherence tomography to monitor corneal burn and treatment response in vivo.

Contemporary perspectives on metabolic surgery for type 2 diabetes: surgical techniques, outcomes, and complications.

Related Experiment Videos

Transforming growth factor-beta in benign and malignant prostate.

Area of Science:

Background:

Purpose of the Study:

Main Methods:

Main Results:

Conclusions:

Related Concept Videos

Related Articles